The private Canadian biotech is advancing a first-in-class GRP78 inhibitor into Phase III studies in gastrointestinal cancers after interim Phase II data suggested potential to improve upon on standard-of-care efficacy.

Public Company Edition: Genenta, Cingulate, ImmixBio, Bionomics and NeuroSense launched initial public offerings, grossing just $118m between them. But Amylyx, with a recently filed ALS drug, has filed to raise up to $100m. In follow-on offerings, Legend took advantage of ASH goodwill to raise $300m. 

The company has begun a limited release of the radial artery access devices it added to its neurovascular therapies business when it quietly acquired RIST Neurovascular in 2020.

Canadian generic oncology specialist Waverley Pharma has cross-listed on the Frankfurt Stock Exchange.